Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810960 · ClinicalTrials.gov registry record
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
A clinical trial of Alzheimers Disease, sponsored by Eisai Korea.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT06810960: Recruiting study of Alzheimers Disease, sponsored by Eisai Korea.
NCT06810960 is a study of Alzheimers Disease that is actively recruiting participants, run by Eisai Korea. The registered enrollment target is 3,000 participants, below the 3,906-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06810960, a study of Alzheimers Disease, is actively recruiting participants, sponsored by Eisai Korea.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.
Primary Outcome
AESI will include ARIA-E, ARIA-H, symptomatic ARIA-E, symptomatic ARIA-H, and ICH greater-than 1 cm.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
New Jersey
- Eisai Trial Site #1 - Nutley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2029-12-31 |
What NCT06810960 shows while recruiting
NCT06810960 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,906-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06810960 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06810960 about?
NCT06810960 is a clinical study titled "A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease". The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (IC...
What is the current status of trial NCT06810960?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2025-02-24. Estimated completion is 2029-12-31.
What conditions does trial NCT06810960 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT06810960?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06810960?
This trial is sponsored by Eisai Korea, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810960 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06810960's enrollment target sits among peer trials
3,000 5th of 147 higher than 143 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
University of Central Florida Music Study
RECRUITING · NA
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI